Biologic therapies: What and when?

Journal of Clinical Pathology

Volumn 60, Issue 1, 2007, Pages 8-17

  Johnston, Sarah L ^a  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; BEVACIZUMAB; CETUXIMAB; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DACLIZUMAB; DOXORUBICIN; EFALIZUMAB; ETANERCEPT; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; HYBRID PROTEIN; IBRITUMOMAB TIUXETAN; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; OKT 3; OMALIZUMAB; PLACEBO; PREDNISONE; RITUXIMAB; STEROID; TOSITUMOMAB I 131; TRASTUZUMAB; UNINDEXED DRUG; VINCRISTINE;

ANKYLOSING SPONDYLITIS; ASTHMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARDIAC GRAFT REJECTION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROHN DISEASE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERANCE; FOLLICULAR LYMPHOMA; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY GRAFT REJECTION; LIVER GRAFT REJECTION; MONOTHERAPY; NONHODGKIN LYMPHOMA; NONHUMAN; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS;

ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; BIOLOGICAL RESPONSE MODIFIERS; DRUG APPROVAL; HUMANS; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846463374     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.032300     Document Type: Review

References (55)

1. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495- 7.
2. Uhr JW. The 1984 Nobel Prize in Medicine. Science 1984;226:1025-8.
3. Reichert JM. Monoclonal antibodies in the clinic. Nature Biotechnol 2001;19:819-22.
4. Bell S, Kamm MA. Antibodies to tumour necrosis factor α as treatment for Crohn's disease. Lancet 2000;355:858-60.
5. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
6. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85.
7. Rutgeerts P, Sandborn WJ, Faegan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76.
8. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
9. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
10. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
11. Lipsky PE, Van Der Heijde DMFM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
12. National Institute for Clinical Excellence. Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. Technology appraisal guidance number 36. London: National Institute for Clinical Excellence, 2002.
13. Lamprecht P, Voswinkel J, Lilienthal T, et al. Effectiveness of TNFα blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology 2002;41:1303-7.
14. Stone JH, Uhlfelder ML, Hellmann DB, et al. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 2001;44:1149- 54.
15. The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352:351-61.
16. Booth A, Harper L, Hammad T, et al. Prospective study of TNFα blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vascultis. J Am Soc Nephrol 2004;15:717-21.
17. Ellis CN, Krueger GG, for the Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248-55.
18. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346:1692-8.
19. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598-608.
20. Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-95.
21. Zoja F, De Vita S, Russo D, et al. Rituximab for the treatment of type II mixed cryoglobulinaemia. Arthritis Rheum 2002;46:2252-4.
22. Ferri C, Mascia MT. Cryoglobulinemic vasculitis. Curr Opin Rheumatol 2006;18:54-63.
23. Buhaescu I, Covic A, Levy J. Systemic vasculitis: still a challenging disease. Am J Kidney Dis 2005;46:173-85.
24. Edwards JCW, Szczepański L, Szechiński J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
25. Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 2005;17:550-7.
26. Johnston S, Kennedy C. Pemhigus foliaceus. N Engl J Med 2005;353:2589.
27. 131I- Tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441-9.
28. Vincenti F, Kirkman R, Light S, et al. Interleukin-2- receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998;338:161-5.
29. Beniaminovitz A, Itescu S, Lietz K, et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2-receptor with a monoclonal antibody. N Engl J Med 2000;342:613-19.
30. Hershberger RE, Starling RC, Eisen HJ, et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 2005;352:2705-13.
31. Isaacs JD, Manna VK, Rapson N, et al. Campath-1H in rheumatoid arthritis-an intravenous dose-ranging study. Br J Rheumatol 1996;35:231-40.
32. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004-13.
33. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353:1912-25.
34. 7 integrin. N Engl J Med 2005;352:2499-507.
35. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
36. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23.
37. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-8.
38. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375-81.
39. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-74.
40. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924-33.
41. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907-15.
42. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor a inhibition. N Engl J Med 2005;353:1114-23.
43. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005;353:770-81.
44. Milgrom H, Fick RB, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 1999;341:1966-73.
45. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
46. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
47. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
48. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
49. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
50. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
51. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncitial virus monoclonal antibody, reduces hospitalization from respiratory syncitial virus infection in high-risk infants. Pediatrics 1998;102:531-7.
52. Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004;351:2069- 79.
53. Plötz SG, Simon HU, Darsow U, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003;349:2334-9.
54. Griffiths I, Silman A, Symmons D, et al. BSR biologics registry. Rheumatology 2004;43:1463-4.
55. Mayor S. The public needs better understanding of drug regulation. BMJ 2006;332:990.